Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in fibrostenotic Crohn's disease (phase IIa, Belgium)
2020-005770-99Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Spesolimab with Placebo (2 arms). Primary endpoint: Maintained Symptomatic Stenosis Response. Started Jul 2021; status: completed.
02
Drugs
spesolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2020-005770-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005770-99.